Champions Oncology to Participate in 14th Annual World Preclinical Congress

Hackensack, NJ – June 10, 2015 – Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced participation as a corporate sponsor of the 14th Annual World Preclinical Congress . The program, which focuses on the challenges and opportunities in drug discovery and development facing scientists focused in preclinical research, will also feature several presentations about Champions TumorGraft®  patient-derived xenograft (PDX) and ImmuoGraft models.

Neal Goodwin, PhD, Vice President, Corporate Research & Development will conduct a short course on PDX Model Development, host a roundtable discussion on Expanding the Utility of PDX Platforms, and address delegates in the PreClinical Models and Imaging in Oncology track on Patient-Derived Xenograft Clinical Trial Programs.  Keren Paz, PhD, Chief Scientific Officer, will present Personalized Mouse Models for Preclinical Testing of Drugs Targeting Immune Checkpoints to delegates in the Tumor Models for Cancer Immunotherapy track.

The Congress takes place June 10-12, 2015 in Boston, MA.